Publicaciones en las que colabora con Carlos Ferrándiz Foraster (17)

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts

    Medicine (United States), Vol. 96, Núm. 26

2016

  1. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

    Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

  2. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis

    Pharmacogenomics Journal, Vol. 15, Núm. 4, pp. 322-325

2014

  1. Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas)

    Actas Dermo-Sifiliograficas

  2. Spanish adaptation of the european guidelines for the evaluation and treatment of actinic keratosis

    Actas Dermo-Sifiliograficas, Vol. 105, Núm. 4, pp. 378-393

2013

  1. Genome-wide transcriptional analysis of T cell activation reveals differential gene expression associated with psoriasis

    BMC Genomics, Vol. 14, Núm. 1

  2. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment

    Actas Dermo-Sifiliograficas

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European Medicines Agency: A multicenter observational study

    Actas Dermo-Sifiliograficas, Vol. 102, Núm. 5, pp. 354-364

2007

  1. Revisión de la literatura dermatológica con criterios de la medicina basada en la evidencia. Una nueva sección

    Piel

1995

  1. Erythromycin lauryl sulphate in combination with tretinoin in the topical treatment of acne vulgaris. A multicentre double-blind clinical trial

    Journal of Dermatological Treatment, Vol. 6, Núm. 1, pp. 47-50

1994

  1. Eritrodermias infantiles

    Madrid : Grupo Aula Médica, D.L. 1994

1992

  1. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses

    Arzneimittel-Forschung/Drug Research, Vol. 42, Núm. 5 A, pp. 767-773